What is lymphangioleiomyomatosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Lymphangioleiomyomatosis (LAM)?

Lymphangioleiomyomatosis (LAM) is a rare, systemic neoplastic disease that almost exclusively affects women of reproductive age, characterized by proliferation of abnormal smooth muscle-like cells (LAM cells) leading to cystic lung destruction, lymphatic involvement with chylous fluid accumulations, and abdominal tumors including angiomyolipomas and lymphangioleiomyomas 1.

Pathophysiology

LAM is caused by mutations in the TSC1 or TSC2 genes, which encode hamartin and tuberin respectively—two proteins that control the mechanistic target of rapamycin (mTOR) signaling pathway 2. These LAM cells coexpress smooth muscle and melanocytic markers and have metastatic potential 3, 4. Female hormones, particularly estrogens, significantly influence disease progression 4.

Clinical Presentation

LAM occurs in two forms:

  • Sporadic LAM: Occurs independently in women
  • TSC-associated LAM: Occurs in patients with tuberous sclerosis complex, an autosomal-dominant syndrome 5

Common Symptoms

  • Progressive dyspnea (most frequent symptom at diagnosis) 6
  • Recurrent spontaneous pneumothorax (typical presentation) 6, 2
  • Chest pain and coughing 4
  • Chylothorax (chylous pleural effusions) 1

Extrapulmonary Manifestations

  • Renal angiomyolipomas 6, 2
  • Lymphangioleiomyomas (cystic lymphatic structures) 1
  • Chylous ascites 1

Diagnostic Features

Pulmonary function testing reveals reduced flow rates (FEV₁) and decreased lung diffusion capacity 2, 5. Exercise testing may demonstrate hypoxemia and ventilatory limitation 2.

Imaging shows characteristic diffuse pulmonary cysts on computed tomography 1.

A critical diagnostic algorithm: For patients with characteristic cystic abnormalities on CT but lacking confirmatory features (tuberous sclerosis complex, angiomyolipomas, chylous effusions, or lymphangioleiomyomas), VEGF-D testing should be performed before considering lung biopsy 1.

Prognosis and Natural History

LAM is a slowly progressive disease with variable clinical phenotypes and rates of progression 2. Recent advances in understanding the molecular mechanisms and the introduction of mTOR inhibitors have significantly improved prognosis 3. The disease severity can be assessed through CT quantification, pulmonary function testing, 6-minute walk tests, and serum VEGF-D levels 5.

References

Research

Brazilian Thoracic Association recommendations for the management of lymphangioleiomyomatosis.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2025

Research

Lymphangioleiomyomatosis: A Review.

Archives of pathology & laboratory medicine, 2024

Research

Lymphangioleiomyomatosis.

Presse medicale (Paris, France : 1983), 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.